Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes
Main finding · MALEResult — go to the resultAdjusted hazard ratio 0.65 95% CI 0.44–0.94Authors' conclusion
In patients with PAD and diabetes, GLP1-RA exposure was associated with favorable clinical outcomes. Time-aligned analyses demonstrated a lower risk of all-cause mortality, while sustained GLP1-RA exposure was associated with lower MALE risk.
Study context
- Population
- Adults with peripheral artery disease (PAD) and diabetes, Clalit Health Services database
- Participants
- 20,031 adults
- Exposure
- GLP-1 RA exposure vs non-use
- GLP1-RAn = 5,960
- Non-usersn = 14,071reference
- Outcome
- MALE: lower-limb revascularization or amputation
Methodological detailsinverse probability of treatment weighting, incident-treatment risk-set approach, time-varying persistent-use model
- Inverse probability of treatment weighting
- Incident-treatment risk-set approach
- Time-varying persistent-use model
Main finding
MALE
Adjusted hazard ratio
0.65
95% CI 0.44–0.94
P = 0.022
GLP1-RAvs Non-users
adjusted HR 0.65 (95% CI 0.44–0.94); P = 0.022
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortalityTime-aligned risk-set analysis | 0.80 (0.73–0.88) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Revascularization, major amputation and all-cause mortality (IPTW-weighted analysis)
- GLP1-RA exposure associated with lower risks of revascularization, major amputation and all-cause mortality
Original publication
Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes. Diabetes Metab. Published 24 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →